The FDA already approved the PFS for nAMD, DME and RVO in July 2024. Vabysmo’s Growth Fuels RHHBY The drug’s stellar performance has fueled Roche’s top-line growth since approval. Sales ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five ...

Abbey said the approval of the Vabysmo prefilled syringe (faricimab, Genentech) for the treatment of retinal vein occlusion (RVO) added durability to some patients’ treatment. Faricimab is ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of CHF 432 million ($485 ...

Vabysmo (faricimab) has been recommended by the EMA's human medicines committee as a treatment for neovascular or wet age-related macular degeneration (AMD) and diabetic macular oedema (DME), so ...

Reports Q4 revenue $1.8M.Tom Burns, Chief Financial Officer of XOMA (XOMA) Royalty, commented, “Based upon the anticipated incoming cash ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 13, 2025 /EINPresswire / -- How will the Vabysmo Market Experience Significant Expansion? The Vabysmo market is on a strong growth trajectory ...

Vision is a gift that many of us take for granted, but for those suffering from retinal vein occlusion (RVO), every day can ...